The purpose of this study is to compare the efficacy of pomalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of pomalidomide and low dose dexamethasone without pembrolizumab in terms of progression-free survival (PFS) in participants with refractory or relapsed and refractory multiple myeloma (rrMM) who have undergone at least 2 lines of prior treatment.
SparkCures ID | 783 |
---|---|
Trial Phase | Phase 3 |
Enrollment | 300 Patients |
Treatments |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersSparkCures is working closely with Merck Sharp & Dohme Corp. to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors